ArticleGenome biology2013
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
Article in Genome biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 46 citations in OpenAlex.
- An attractor state zone precedes neural crest fate in melanoma initiation.bioRxiv : the preprint server for biology · 2024Article
- Imaging-Based Efficacy Evaluation of Cancer Immunotherapy in Engineered Tumor Platforms and Tumor Organoids.Advanced healthcare materials · 2024Review
- Review
- An overview of mouse models of hepatocellular carcinoma.Infectious agents and cancer · 2023Review
- Non-Invasive Monitoring of Cutaneous Wound Healing in Non-Diabetic and Diabetic Model of Adult Zebrafish Using OCT Angiography.Bioengineering (Basel, Switzerland) · 2023Article
- Disease modeling by efficient genome editing using a near PAM-less base editor in vivo.Nature communications · 2022Article
- Melanoma models for the next generation of therapies.Cancer cell · 2021Review
- SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance.eLife · 2021Article
- Article
- Review
- The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities.International journal of molecular sciences · 2018Review
- Mouse Models for Cancer Immunotherapy Research.Cancer discovery · 2018Review
- Cancer modeling by Transgene Electroporation in Adult Zebrafish (TEAZ).Disease models & mechanisms · 2018Article
- Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.The Journal of clinical investigation · 2018Article
- Macrophage-Dependent Cytoplasmic Transfer during Melanoma Invasion In Vivo.Developmental cell · 2017Article
- Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer.International journal of molecular sciences · 2017Review
- From fish bowl to bedside: The power of zebrafish to unravel melanoma pathogenesis and discover new therapeutics.Pigment cell & melanoma research · 2017Review
- Article
- Tumor diversity and evolution revealed through RADseq.Oncotarget · 2017Article
- Melanoma genome evolution across species.BMC genomics · 2017Article
Corrections and comments
- Commented on by
Authors and funding
40 authors at 8 institutions in 4 countries.
Funding
Abstract
backgroundMelanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process.
resultsTo decipher the genetics of these melanomas, we sequence the protein coding exons of 53 primary melanomas generated from several BRAF(V600E) or NRAS(Q61K) driven transgenic zebrafish lines. We find that engineered zebrafish melanomas show an overall low mutation burden, which has a strong, inverse association with the number of initiating germline drivers. Although tumors reveal distinct mutation spectrums, they show mostly C > T transitions without UV light exposure, and enrichment of mutations in melanogenesis, p53 and MAPK signaling. Importantly, a recurrent amplification occurring with pre-configured drivers BRAF(V600E) and p53-/- suggests a novel path of BRAF cooperativity through the protein kinase A pathway.
conclusionThis is the first analysis of a melanoma mutational landscape in the absence of UV light, where tumors manifest with remarkably low mutation burden and high heterogeneity. Genotype specific amplification of protein kinase A in cooperation with BRAF and p53 mutation suggests the involvement of melanogenesis in these tumors. This work is important for defining the spectrum of events in BRAF or NRAS driven melanoma in the absence of UV light, and for informed exploitation of models such as transgenic zebrafish to better understand mechanisms leading to human melanoma formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.